Nanomedical Diagnostics Announces Peer-Reviewed Publication Demonstrating High Sensitivity and Selectivity With the AGILE R100 Label-Free Electronic Assay

Co-authored by scientists from UCSD and UCI, the publication highlights enzyme, antibody, and insulin experiments that showcase AGILE R100’s ability to exceed current protein characterization methods.


Nanomedical Diagnostics, a biotech company driving the use of label-free graphene biosensor assays in life science research and diagnostics, announces a publication co-authored by researchers from UC San Diego and UC Irvine titled “Large Scale Commercial Fabrication of High Quality Graphene-Based Assays for Biomolecule Detection” in the journal Sensors & Actuators B: Chemical (Lerner 2016). The paper describes the company’s translation of Nobel Prize-winning nanoscience into standard electronics assembly processes to manufacture AGILE R100, a new benchtop assay built on break-through field effect biosensing technology. An overview of protein characterization experiments utilizing AGILE R100 and demonstrating high sensitivity and selectivity is provided.

The first experiment depicts the use of antibodies to detect insulin at a lower limit of detection of 100 pM, in line with costly, non-portable high-end surface plasmon resonance (SPR) label-free systems. “Insulin is a key hormone in the regulation of glucose and energy,” says Nanomedical Diagnostics CEO, Ross Bundy. “The ability of the small 2 lb. AGILE R100 system to measure at this clinically relevant level of sensitivity has far-reaching implications for the monitoring and treatment of diabetes.” In addition to high sensitivity, AGILE R100 detected insulin in diluted serum, showing high selectivity enabled by effective blocking chemistry. The blocking chemistry enables the biosensor to perform well in complex media such as whole blood, blood fractions, cell growth media, and DMSO.

The second kinetic characterization experiment run on the AGILE R100 system highlights a Rho GTPase and GAP protein kinetic interaction, and the association and dissociation rates of the two biomolecules were automatically calculated by the system software. AGILE R100’s calculated equilibrium dissociation constant aligns closely with literature value, demonstrating a high degree of accuracy.

AGILE R100 is a benchtop label-free assay that provides sensitive real-time binding kinetics and concentration data for optimizing lead compounds during drug discovery. Unlike SPR or biolayer interferometry (BLI) techniques, the all-electronic, field effect biosensing technology can detect small molecules and fragments with no lower size limit in up to 10% DMSO in as little as 10 µL.

“These experiments show AGILE R100 as a viable, even preferable alternative to SPR or BLI tools, as it uses less reagents and time to obtain data while providing a more efficient user experience,” continues CEO Ross Bundy. “AGILE R100 requires as little as 10 µL of sample compared to 200 µL for a high-end BLI tool and begins collecting kinetic data within 5 minutes of sample preparation, compared to over 3 hours on a common SPR tool. It ushers in a new era of dynamic protein characterization enabled by cutting edge field effect biosensing technology.”

AGILE R100 is available for commercial sale, for research use only. For more information, visit

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a biotech company based in San Diego, CA. Nanomed has developed a breakthrough all-electronic assay with field effect biosensing technology that provides real-time, label-free kinetic binding and concentration data. AGILE biosensor chips at the heart of the assay leverage the highly sensitive nanomaterial graphene to unite biology with electronics, delivering the unique ability to sense small molecules with no lower size limit in complex media such as DMSO, and use unprecedentedly small amounts of sample.